Skip to main content
. 2015 Mar 6;2015(3):CD003443. doi: 10.1002/14651858.CD003443.pub3

Wang 2008c.

Methods Allocation: randomised.
Blindness: not stated.
Duration: 8 weeks, 2003‐2007 (one‐week wash‐out)
Setting: Baoji rehabilitation hospital, Shanxi, China.
Participants Diagnosis: schizophrenia CCMD‐3.
N = 64.
Age: Quetiapine: 66.08 ± 4.22 years; perphenazine: 65.73 ± 5.53 years.
Sex: F27, M37 (Quetiapine (n = 32): M17 F15; perphenazine (n = 32): M20 F12).
History: length of illness Quetiapine: 3.6 ± 0.5months; perphenazine: 3.4 ± 0.6months.
Included: Schizophrenia CCMD‐3; age ≥ 60 years, first episode; BPRS ≥ 35.
Exclusion: drug abuse; organic dysphrenia.
Consent: not stated..
Interventions 1. Perphenazine: start from 4 mg/day to treatment dosage: 20‐40 mg/day, average:24.5 ± 5.3mg/day, n = 32.
2. Quetiapine: start from 50 mg/day to the treatment dosage: 200‐400 mg/day, average dosage: 258.92 ± 28.13mg/day, n = 32.
Outcomes Lab data: blood test, urine test, liver function, kidney function, ECG, blood pressure.
Adverse events.
BPRS score.
TESS score.
Clinical prognosis assessment: decreased rate of BPRS score ≥ 75%‐‐recovery; 50% to 74% markedly improved; 25% to 49% improved; < 25% no effect.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Randomised – no further details.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection bias) 
 All outcomes Unclear risk Not described.
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk In the quetiapine group, n = 1 left the study due to drowsiness. In the perphenazine group n = 3 left due to EPS. Missing data from participants leaving the study early were not included in analyses.
Selective reporting (reporting bias) Unclear risk None detected.
Other bias Unclear risk Funding: not stated.
Rating scales: raters not stated to be independent of treatment.